Autoimmune & Immunology Conferences

Given autoimmune disorders are one the largest healthcare burdens after oncology, and the current standard of care risking infection and low efficacy, the demand and opportunity to develop precision therapies is growing. It is therefore hugely promising that 506 trials were initiated in H1 2024 alone to pioneer future innovations needed by patients.

With a specific focus on cell therapies, Tregs, immune tolerance, cytokines and targeting the inflammasome and complement pathways, our mission is to help organisations uncover translational opportunities to accelerate the development and approval of more precise therapies that address the patient health burden associated with autoimmunity.